论文部分内容阅读
目的观察并分析糖尿病肾病(DN)与2型糖尿病(T2DM)早期发生和发展与血清脂联素的关系。方法 50例2型糖尿病患者、50例糖尿病肾病患者和50例健康体检者分别为2型糖尿病组、糖尿病肾病组和健康检测对照组,均采用酶联免疫吸附试验(ELISA)进行检测,并进行回顾性试验分析,观察2型糖尿病、糖尿病肾病和脂联素浓度的关系。结果健康体检者体内血清脂联素浓度明显要高于单纯2型糖尿病和糖尿病肾病患者体内的脂联素浓度,差异均具有统计学意义(P<0.05);且2型糖尿病患者血清脂联素浓度明显高于早期糖尿病肾病患者,差异有统计学意义(P<0.05)。结论 2型糖尿病、糖尿病肾病和脂联素浓度的关系紧密,因此针对糖尿病肾病和2型糖尿病的诊断与治疗可以分析脂联素的浓度作为判定依据,以提高治疗效果。
Objective To observe and analyze the relationship between early onset and development of diabetic nephropathy (DN) and type 2 diabetes (T2DM) and serum adiponectin. Methods Fifty patients with type 2 diabetes mellitus, 50 patients with diabetic nephropathy and 50 healthy subjects were type 2 diabetes mellitus, diabetic nephropathy group and healthy control group, all detected by enzyme-linked immunosorbent assay (ELISA) Retrospective analysis of the experimental observation of type 2 diabetes, diabetic nephropathy and adiponectin concentrations. Results Serum adiponectin concentrations in healthy subjects were significantly higher than those in patients with type 2 diabetes mellitus and diabetic nephropathy, the differences were statistically significant (P <0.05). Serum adiponectin in type 2 diabetic patients The concentration was significantly higher than the early diabetic nephropathy patients, the difference was statistically significant (P <0.05). Conclusions Type 2 diabetes mellitus, diabetic nephropathy and adiponectin concentration are closely related. Therefore, for the diagnosis and treatment of diabetic nephropathy and type 2 diabetes, the concentration of adiponectin can be analyzed as the basis for determination to improve the therapeutic effect.